Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Apoptosis ; 13(1): 11-32, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17968659

RESUMO

Apoptosis plays a central role not only in the physiological processes of kidney growth and remodeling, but also in various human renal diseases and drug-induced nephrotoxicity. We present in a synthetic fashion the main molecular and cellular pathways leading to drug-induced apoptosis in kidney and the mechanisms regulating it. We illustrate them using three main nephrotoxic drugs (cisplatin, gentamicin, and cyclosporine A). We discuss the main regulators and effectors that have emerged as key targets for the design of therapeutic strategies. Novel approaches using gene therapy, antisense strategies, recombinant proteins, or compounds obtained from both classical organic and combinatorial chemistry are examined. Finally, key issues that need to be addressed for the success of apoptosis-based therapies are underlined.


Assuntos
Proteínas Reguladoras de Apoptose/metabolismo , Apoptose/efeitos dos fármacos , Caspases/metabolismo , Cisplatino/toxicidade , Ciclosporina/toxicidade , Gentamicinas/toxicidade , Rim/efeitos dos fármacos , Animais , Cisplatino/metabolismo , Ciclosporina/metabolismo , Gentamicinas/metabolismo , Humanos , Rim/citologia , Redes e Vias Metabólicas , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Insuficiência Renal/metabolismo
2.
Antimicrob Agents Chemother ; 45(9): 2643-7, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11502544

RESUMO

The stability and compatibility of ceftazidime have been examined in the context of its potential use in concentrated solutions for continuous infusion in patients suffering from severe nosocomial pneumonia and receiving other intravenous medications by the same route. Ceftazidime stability in 4 to 12% solutions was found satisfactory (<10% degradation) for 24 h if kept at a temperature of 25 degrees C (77 degrees F) maximum. Studies mimicking the simultaneous administration of ceftazidime and other drugs as done in clinics showed physical incompatibilities with vancomycin, nicardipine, midazolam, and propofol and a chemical incompatibility with N-acetylcystein. Concentrated solutions (50 mg/ml) of erythromycin or clarithromycin caused the appearance of a precipitate, whereas gentamicin, tobramycin, amikacin, isepamicin, fluconazole, ketamine, sufentanil, valproic acid, furosemide, uradipil, and a standard amino acid solution were physically and chemically compatible.


Assuntos
Ceftazidima/administração & dosagem , Cefalosporinas/administração & dosagem , Ceftazidima/efeitos adversos , Ceftazidima/metabolismo , Ceftazidima/uso terapêutico , Cefalosporinas/efeitos adversos , Cefalosporinas/metabolismo , Cefalosporinas/uso terapêutico , Cuidados Críticos , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/metabolismo , Incompatibilidade de Medicamentos , Estabilidade de Medicamentos , Quimioterapia Combinada , Humanos , Infusões Intravenosas , Midazolam/farmacologia , Nicardipino/farmacologia , Pneumonia Bacteriana/tratamento farmacológico , Pneumonia Bacteriana/metabolismo , Propofol/farmacologia , Temperatura , Vancomicina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA